<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664869</url>
  </required_header>
  <id_info>
    <org_study_id>Finnbladder-10</org_study_id>
    <nct_id>NCT03664869</nct_id>
  </id_info>
  <brief_title>Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer</brief_title>
  <acronym>FB10</acronym>
  <official_title>Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnbladder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disease recurrence and progression is a major issue in high risk non-muscle-invasive bladder
      cancer (NMIBC).

      The current study compares two adjuvant instillation therapies in the treatment of high risk
      NMIBC. After resection of the tumour(s), patients will receive either traditional regimen of
      Bacillus Calmette-Guérin (BCG) instillations or combination treatment consisting of
      sequential BCG-instillations and mitomycin C instillations administered with electromotive
      drug administration (EMDA) device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease. The patients with
      NMIBC may be categorized in three risk groups according to the risk of recurrence and
      progression characterized by the disease. The treatment of high risk NMIBC includes a
      transurethral resection of the tumour(s), which is followed by an adjuvant instillation
      therapy, aiming to reduce the risk of recurrence and progression. Intravesical bacillus
      Calmette-Guérin (BCG) treatment is been the most effective single agent against NMIBC, and it
      is referred to as the gold standard in the treatment of high risk disease.

      BCG is a solution of live, attenuated mycobacterium bovis bacteria, which is administered
      intravesically in an outpatient clinic. BCG activates an immunological reaction in the
      bladder wall, which leads to antitumour effect by activation of macrophages, T-cells, and
      natural killer (NK) cells. BCG treatment comprises an induction period, which includes six
      weekly instillations. This is followed by maintenance period including monthly or repeated
      series of three weekly instillations up to 1-3 years.

      Other instillation therapies include intravesically administered chemotherapy. Mitomycin C
      (MMC) is the most used chemotherapeutic agent. MMC provides a better tolerated side effect
      profile, but is less effective against high risk NMIBC than BCG, when MMC is used as a single
      agent. Combinations of BCG- and MMC treatment has also been described with various results.
      The rationale for combining BCG and MMC is to enhance the absorption of BCG as MMC might
      cause disruption of bladder mucosa, which makes the mucosa more permeable thus enhancing the
      absorption of BCG. However, it is also hypothesized, that BCG may also work synergistic in
      favor of MMC.

      The absorption and effect of MMC may be enhanced with electromotive drug administration
      (EMDA) device. After instillation of MMC, an electric field is conducted in the bladder with
      EMDA device via catheter and electrodes, which are placed in the bladder and lower abdomen
      skin. Electric field creates movement of sodium ions and water into the bladder wall, which
      creates electro-osmotic drag of MMC molecules. In a laboratory setting, EMDA-MMC instillation
      results in 4-7 times greater concentration of MMC in the deeper layers of the bladder wall
      than passively administered MMC instillation. EMDA-MMC treatment may also be combined with
      BCG treatment administering BCG and EMDA-MMC instillations sequentially. Results from a
      prospective randomized trial suggested, that sequential EMDA-MMC and BCG treatment might be
      even more effective against NMIBC than BCG therapy alone in terms of recurrence, progression
      and overall survival.

      The current study is a prospective, open label, phase III randomized study allocating
      patients with high risk NMIBC to receive adjuvant instillation therapy either as traditional
      BCG treatment, or sequential BCG- and EMDA-MMC treatment. The aim of the study is to compare
      effectiveness and tolerability of the two treatment regimens in preventing recurrence and
      progression of high risk NMIBC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bladder cancer recurrence rate</measure>
    <time_frame>2 years</time_frame>
    <description>Any bladder cancer recurrence at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of bladder cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Progression of bladder cancer in terms of T-category compared to the last resected tumour prior to randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Death due bladder cancer or other reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NMIBC24 quality of life questionnaire (QLQ) score</measure>
    <time_frame>2 years</time_frame>
    <description>Side-effects related to the treatment measured with EORTC QLQ-NMIBC24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>2 years</time_frame>
    <description>Complications or adverse events related to bladder cancer or the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3
Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.
Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG instillation therapy</intervention_name>
    <description>Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>BCG</other_name>
    <other_name>BCG-MEDAC</other_name>
    <other_name>OncoTICE</other_name>
    <other_name>ImmuCyst</other_name>
    <other_name>TheraCys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential BCG and EMDA mitomycin C</intervention_name>
    <description>Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.
BCG instillation is performed as a standard instillation.
Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Sequential BCG and EMDA-MMC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven non-muscle-invasive tumour types confined to the urinary bladder

          -  Carcinoma in situ with or without a papillary tumour(s)

          -  Ta tumour(s) of high-grade

          -  Any T1 tumour(s)

          -  Written informed consent is required from every eligible patient

          -  Second resection performed in case of T1 tumour

          -  Adequate physical and mental condition to participate in the study (as judged by
             treating physician

        Exclusion Criteria:

          -  Ta low grade tumour(s)

          -  Muscle invasive (pT≥2) tumors

          -  Urothelial cancer involving the prostatic urethra or upper urinary tract

          -  Non‐urothelial bladder cancer.

          -  Prior BCG failure (If the patient has previously been successfully treated with BCG,
             and duration from the last instillation is &gt;12 months, participation may be
             considered, if bladder preserving is chosen)

          -  Prior or concurrent immunotherapy

          -  Any medication or condition considered as contraindication to BCG or MMC (as judged by
             the treating physician)

          -  Urethral stricture, stone disease, chronic urinary tract infection or any other
             urological condition that may comprise study participation (as judged by the treating
             physician)

          -  Known allergy to MMC or BCG

          -  Age &lt; 18 years

          -  Pregnancy or lactating patient

          -  Other untreated or unstable malignancy in risk of recurrence/progression (as judged by
             the treating physician)

          -  Cardiac pacemaker

          -  Expected survival time less than one year

          -  Expected poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Boström, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Turku University Hospital, Hospital District of Southwest Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pertti T Nurminen, MD</last_name>
    <phone>+358 2 3135922</phone>
    <email>pertti.nurminen@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riikka Järvinen, MD, PhD</last_name>
    <phone>+358 50 427 1015</phone>
    <email>riikka.jarvinen@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HYKS Peijas Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riikka Järvinen, MD, PhD</last_name>
      <phone>+358 50 4271015</phone>
      <email>riikka.jarvinen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Riikka Järvinen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jyväskylä Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Seikkula, MD, PhD</last_name>
      <phone>+358 14 269 1811</phone>
      <email>heikki.seikkula@ksshp.fi</email>
    </contact>
    <investigator>
      <last_name>Heikki Seikkula, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Central hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taina Isotalo, MD, PhD</last_name>
      <phone>+358 3 819 11</phone>
      <email>taina.isotalo@phsotey.fi</email>
    </contact>
    <investigator>
      <last_name>Taina Isotalo, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mikkeli Central Hospital</name>
      <address>
        <city>Mikkeli</city>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niilo Hendolin, MD</last_name>
      <phone>+358 1 53 511</phone>
      <email>niilo.hendolin@essote.fi</email>
    </contact>
    <investigator>
      <last_name>Niilo Hendolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timo Marttila, MD</last_name>
      <phone>+358 6 415 4111</phone>
      <email>timo.marttila@epshp.fi</email>
    </contact>
    <investigator>
      <last_name>Timo Marttila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Pogodin-Hannolainen, MD</last_name>
      <phone>+358 3 311 611</phone>
      <email>dimitri.pogodin-hannolainen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Dimitri Pogodin-Hannolainen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pertti T Nurminen, MD</last_name>
      <phone>+358 2 3135922</phone>
      <email>pertti.nurminen@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Pertti T Nurminen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008 Winter;10(1):31-43.</citation>
    <PMID>18470273</PMID>
  </reference>
  <reference>
    <citation>Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. Epub 2006 Jan 17.</citation>
    <PMID>16442208</PMID>
  </reference>
  <reference>
    <citation>Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.</citation>
    <PMID>27324428</PMID>
  </reference>
  <reference>
    <citation>Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 1990 Nov;144(5):1248-51.</citation>
    <PMID>2122008</PMID>
  </reference>
  <reference>
    <citation>Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol. 2010;2010:357591. doi: 10.1155/2010/357591. Epub 2010 Sep 1. Review.</citation>
    <PMID>20862387</PMID>
  </reference>
  <reference>
    <citation>Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Böhle A. NK cells are essential for effective BCG immunotherapy. Int J Cancer. 2001 Jun 1;92(5):697-702.</citation>
    <PMID>11340575</PMID>
  </reference>
  <reference>
    <citation>Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180-3.</citation>
    <PMID>820877</PMID>
  </reference>
  <reference>
    <citation>Pan J, Liu M, Zhou X. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis. Front Med. 2014 Jun;8(2):241-9. doi: 10.1007/s11684-014-0328-0. Epub 2014 May 8.</citation>
    <PMID>24810644</PMID>
  </reference>
  <reference>
    <citation>Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.</citation>
    <PMID>19409692</PMID>
  </reference>
  <reference>
    <citation>Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, Gore JL. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24.</citation>
    <PMID>28027868</PMID>
  </reference>
  <reference>
    <citation>Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002 Nov;168(5):1964-70.</citation>
    <PMID>12394686</PMID>
  </reference>
  <reference>
    <citation>Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004 Apr;63(4):682-6; discussion 686-7.</citation>
    <PMID>15072879</PMID>
  </reference>
  <reference>
    <citation>Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000 Apr;163(4):1124-9.</citation>
    <PMID>10737480</PMID>
  </reference>
  <reference>
    <citation>Di Stasi SM, Giannantoni A, Massoud R, Dolci S, Navarra P, Vespasiani G, Stephen RL. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 1999 Oct 1;59(19):4912-8.</citation>
    <PMID>10519404</PMID>
  </reference>
  <reference>
    <citation>Rajala P, Kaasinen E, Rintala E, Jauhiainen K, Nurmi M, Alfthan O, Lähde M. Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res. 1992;20(3):215-7.</citation>
    <PMID>1615583</PMID>
  </reference>
  <reference>
    <citation>Oosterlinck W, Kirkali Z, Sylvester R, da Silva FC, Busch C, Algaba F, Collette S, Bono A. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol. 2011 Mar;59(3):438-46. doi: 10.1016/j.eururo.2010.11.038. Epub 2010 Dec 7.</citation>
    <PMID>21156335</PMID>
  </reference>
  <reference>
    <citation>Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Mestad O, Rintala E; Nordic Urothelial Cancer Group. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol. 2003 Jun;43(6):637-45.</citation>
    <PMID>12767365</PMID>
  </reference>
  <reference>
    <citation>Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA; Members of Club Urológico Español de Tratamiento Oncológico. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6.</citation>
    <PMID>25301758</PMID>
  </reference>
  <reference>
    <citation>Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003 Sep;170(3):777-82.</citation>
    <PMID>12913696</PMID>
  </reference>
  <results_reference>
    <citation>Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006 Jan;7(1):43-51.</citation>
    <PMID>16389183</PMID>
  </results_reference>
  <results_reference>
    <citation>Gan C, Amery S, Chatterton K, Khan MS, Thomas K, O'Brien T. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes. J Urol. 2016 Jun;195(6):1697-703. doi: 10.1016/j.juro.2016.01.103. Epub 2016 Feb 2.</citation>
    <PMID>26845426</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>recurrence</keyword>
  <keyword>BCG</keyword>
  <keyword>mitomycin C</keyword>
  <keyword>electromotive drug administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

